We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. DICE Therapeutics, Inc. is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
DICE Therapeutics, Inc. is a member of our Medical group, which includes 1183 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. DICE Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for DICE's full-year earnings has moved 10.2% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that DICE has returned about 33.7% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -16.3% on a year-to-date basis. This shows that DICE Therapeutics, Inc. is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Oncolytics Biotech Inc. (ONCY - Free Report) . The stock has returned 31.7% year-to-date.
In Oncolytics Biotech Inc.'s case, the consensus EPS estimate for the current year increased 9.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, DICE Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 558 individual companies and currently sits at #59 in the Zacks Industry Rank. This group has lost an average of 17.2% so far this year, so DICE is performing better in this area. Oncolytics Biotech Inc. is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to DICE Therapeutics, Inc. and Oncolytics Biotech Inc. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. DICE Therapeutics, Inc. is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
DICE Therapeutics, Inc. is a member of our Medical group, which includes 1183 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. DICE Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for DICE's full-year earnings has moved 10.2% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that DICE has returned about 33.7% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -16.3% on a year-to-date basis. This shows that DICE Therapeutics, Inc. is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Oncolytics Biotech Inc. (ONCY - Free Report) . The stock has returned 31.7% year-to-date.
In Oncolytics Biotech Inc.'s case, the consensus EPS estimate for the current year increased 9.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, DICE Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 558 individual companies and currently sits at #59 in the Zacks Industry Rank. This group has lost an average of 17.2% so far this year, so DICE is performing better in this area. Oncolytics Biotech Inc. is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to DICE Therapeutics, Inc. and Oncolytics Biotech Inc. as they could maintain their solid performance.